WallStSmart

Electrocore LLC (ECOR)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 101582% more annual revenue ($35.48B vs $34.90M). MDT leads profitability with a 13.0% profit margin vs -44.1%. MDT earns a higher WallStSmart Score of 61/100 (C+).

ECOR

Avoid

26

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 3/9Altman Z: -14.92

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ECORUndervalued (+84.1%)

Margin of Safety

+84.1%

Fair Value

$34.25

Current Price

$8.72

$25.53 discount

UndervaluedFair: $34.25Overvalued
MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ECOR2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
42.6%10/10

Revenue surging 42.6% year-over-year

Debt/EquityHealth
-1.6710/10

Conservative balance sheet, low leverage

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

ECOR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$72.34M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-478.7%2/10

ROE of -478.7% — below average capital efficiency

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ECOR

The strongest argument for ECOR centers on Revenue Growth, Debt/Equity. Revenue growth of 42.6% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : ECOR

The primary concerns for ECOR are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

ECOR profiles as a hypergrowth stock while MDT is a value play — different risk/reward profiles.

ECOR carries more volatility with a beta of 0.87 — expect wider price swings.

ECOR is growing revenue faster at 42.6% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (61/100 vs 26/100). ECOR offers better value entry with a 84.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Electrocore LLC

HEALTHCARE · MEDICAL DEVICES · USA

electroCore, Inc., a commercial-stage medical device company, is dedicated to the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is headquartered in Rockaway, New Jersey.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?